{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-100522","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2022-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.907108+00:00","generated_at":"2026-06-26T08:30:47.290579+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Frequency Therapeutics cuts 30% of workforce, appoints new CFO","bullets":["Workforce reduction of ~30% to focus capital on FX-322, FX-345, and MS program.","Estimated $1.2M in future cash severance costs; majority implemented, remainder by July 31, 2022.","Richard M. Mitrano appointed principal financial officer, succeeding Peter P. Pfreundschuh.","Mitrano previously Vice President of Finance and Operations since July 2016."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-100522","json":"https://secwatch.observer/filing/0001193125-22-100522.json","markdown":"https://secwatch.observer/filing/0001193125-22-100522.md","text":"https://secwatch.observer/filing/0001193125-22-100522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/0001193125-22-100522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/d348577d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:30:47.290579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d99dc8fb2","claim":"Peter P. Pfreundschuh departed as Chief Financial Officer at Korro Bio, Inc..","evidence_excerpt":"On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer, succeeding Peter P. Pfreundschuh, the Company’s former Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/0001193125-22-100522-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"f9211a2d99","claim":"Richard M. Mitrano was appointed as principal financial officer and principal accounting officer at Korro Bio, Inc..","evidence_excerpt":"On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/0001193125-22-100522-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}